Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Solvay Pharmaceuticals
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have completed S308.3.003 trial
You may not be if
Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003
Clareo Health | An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
